title: Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology.
abstract: Patients with diabetes are at risk of early renal function decline. Therefore, kidney function needs monitoring at least once per year. Once the glomerular filtration rate (GFR) is less than 60 ml/min, the pharmacokinetics of antidiabetic drugs may be altered. Sulfonylurea and glinide therapies are associated with a risk of hypoglycaemia which is increased in the presence of renal impairment. Most sulfonylureas must be discontinued once GFR is <60 ml/min. Some glinides may be continued beyond this threshold, in particular repaglinide, which may be used in dialysis patients. In the absence of comorbidities, metformin can be continued at lower doses until a GFR of 45 ml/min, but must be withdrawn in case of dehydration or during the administration of a nephrotoxic drug including dye for radiological investigations. Glitazones may worsen water and sodium retention in patients with renal impairment. The pharmacokinetics of all DPP-IV inhibitors except linagliptin are altered with impaired renal function. Only sitagliptin, saxagliptin and linagliptin may be used in advanced kidney disease, but experience is as yet very limited. GLP-1 agonists are contraindicated in moderate to advanced kidney disease.
authors.affiliation: Service of Nephrology, Department of Medicine, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. anne.zanchi@chuv.ch
authors.forename: Anne
authors.initials: A
authors.lastname: Zanchi
authors.forename: Roger
authors.initials: R
authors.lastname: Lehmann
authors.forename: Jacques
authors.initials: J
authors.lastname: Philippe
mesh_terms: D000284:Administration, Oral; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D003928:Diabetic Nephropathies / Q000139:chemically induced / Q000150:complications / Q000209:etiology; D005919:Glomerular Filtration Rate / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000150:complications / Q000209:etiology; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000145:classification / Q000493:pharmacokinetics; D015994:Incidence; D008991:Monitoring, Physiologic / Q000592:standards; D051437:Renal Insufficiency / Q000139:chemically induced / Q000209:etiology*; D012307:Risk Factors; D013557:Switzerland / Q000453:epidemiology
chemical_list: D007004:Hypoglycemic Agents